An Operation Warp Speed report last June flagged staffing and quality control concerns at Emergent BioSolutions’ factory in Baltimore. The troubled plant recently had to throw out up to 15 million doses.
Declining infection rates over all masked a rise in more contagious forms of the coronavirus. Vaccines will stop the spread, if Americans postpone celebration just a bit longer.
Vaccine trials are often done in wealthier countries. Scientists say the South Africa experience proves the value of trials in the global south.
The Biden administration plans to make good on a promise to donate $4 billion, while the pharmaceutical company Novavax committed to sell 1.1 billion doses of its vaccine.
Pfizer and Moderna are testing their vaccines on children 12 and older and hope to have results by the summer.
New data from several vaccine trials offer positive signs, but many public health experts say emerging variants mean the next few months will be a race against the virus.
Even with two other vaccines authorized, Novavax is having no trouble recruiting volunteers for its U.S. trial. If all goes well, the U.S. could see 110 million doses in June.
Infectious disease doctors say getting a shot of the J&J vaccine, which has a lower efficacy against the virus than other vaccines, would still be well worthwhile.
An early analysis in Britain found that the vaccine had an efficacy rate of nearly 90 percent. But in a small South Africa trial, the efficacy rate dropped to just under 50 percent.
Multibillion-dollar contracts give drug makers liability shields, patent ownership and leeway on delivery dates and pricing — and promises that much of it will not be made public.
The company agreed to deliver the additional doses of its coronavirus vaccine by the end of July, helping address a looming shortage.
The company could provide at least tens of millions of additional doses of a coronavirus vaccine under an agreement that would give it better access to the supplies it needs to expand manufacturing.
The surge in coronavirus cases worldwide is helping researchers measure more quickly how well their vaccines protect against Covid-19.
Front-runners in the coronavirus vaccine race won’t make nearly as many doses this year as were predicted, but they may kick into high gear next year.
Big profits beckon for pharmaceutical companies, which are already using their work on vaccines to fight efforts in Washington to curb drug prices.
The Maryland company, which has never brought a vaccine to market, has started its Phase 3 trial in the United Kingdom, with plans to begin in the United States in October.
Despite the president’s repeated claims that a vaccine will be available in October, scientists, companies and federal officials all say that most people won’t get one until well into next year.
Inovio, a Pennsylvania biotech company, has spent years claiming to be on the cusp of important vaccines. It has never brought one to market.
The company has received a $1.6 billion grant from the government’s Operation Warp Speed to have 100 million doses ready by early 2021.
Well-timed stock bets have generated big profits for senior executives and board members at companies developing vaccines and treatments.
Novavax just received the Trump administration’s largest vaccine contract. In the Maryland company’s 33-year history, it has never brought a vaccine to market.
The Maryland-based company, which has never brought a product to market before, just made the biggest deal to date with the Trump administration’s Operation Warp Speed.